[1]Samarasekera N, Al-Shahi Salman R, Huitinga I, et al. Brain banking for neurological disorders[J]. Lancet Neurol, 2013, 12(11): 1096-1105.
[2]Yan XX, Ma C, Bao AM, et al. Brain banking as a cornerstone of neuroscience in China[J]. Lancet Neurol, 2015, 14(2): 136.
[3]Tay L, Lim WS, Chan M, et al. New DSM-V neurocognitive disorders criteria and their impact on diagnostic classifications of mild cognitive impairment and dementia in a memory clinic setting[J]. Am J Geriatr Psychiatry, 2015, 23(8): 768-779.
[4]Sachdev PS, Blacker D, Blazer DG, et al. Classifying neurocognitive disorders: the DSM-5 approach[J]. Nat Rev Neurol, 2014, 10(11): 634-642.
[5]Farias ST, Mungas D, Reed BR, et al. The measurement of everyday cognition (ECog): scale development and psychometric properties[J]. Neuropsychology, 2008, 22(4): 531-544.
[6]Tomaszewski Farias S, Mungas D, Harvey DJ, et al. The measurement of everyday cognition: development and validation of a short form of the everyday cognition scales[J]. Alzheimers Dement, 2011,7(6): 593-601.
[7]Montine TJ, Phelps CH, Beach TG, et al. National Institute on AgingAlzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach[J]. Acta Neuropathol, 2012, 123(1): 1-11.
[8]Cairns NJ, Bigio EH, Mackenzie IR, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration[J]. Acta Neuropathol, 2007, 114(1): 5-22.
[9]Deramecourt V, Slade JY, Oakley AE, et al. Staging and natural history of cerebrovascular pathology in dementia[J]. Neurology, 2012, 78(14): 1043-1050.
[10]Dickson DW, Braak H, Duda JE, et al. Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria[J]. Lancet Neurol, 2009, 8(12): 1150-1157.
[11]Mackenzie IR, Neumann M, Bigio EH, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update[J]. Acta Neuropathol, 2010, 119(1): 1-4.
[12]Vonsattel JP, Myers RH, Stevens TJ, et al. Neuropathological classification of Huntington’s disease[J]. J Neuropathol Exp Neurol, 1985, 44(6): 559-577.
[13]Trojanowski JQ, Revesz T, Neuropathology Working Group on MSA. Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy[J]. Neuropathol Appl Neurobiol, 2007, 33(6): 615-620.
[14]Thal DR, Rüb U, Orantes M, et al. Phases of A beta-deposition in the human brain and its relevance for the development of AD[J]. Neurology, 2002, 58(12): 1791-1800.
[15]Braak H, Alafuzoff I, Arzberger T, et al. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry[J]. Acta Neuropathol, 2006, 112(4): 389-404.
[16]Mirra SS, Heyman A, McKeel D, et al. The consortium to establish a registry for Alzheimer’s disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease[J]. Neurology, 1991, 41(4): 479-486.
|